# Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

> **NCT05536128** · PHASE2 · RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT05536128
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05536128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05536128, "Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05536128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*